Leigh Berryman is a seasoned drug development and executive leader with more than 35 years of experience guiding global development programs across the life sciences industry. As Fractional Chief Development Officer, he leads development strategy and execution from discovery through clinical readiness.
Mr. Berryman has led or contributed to hundreds of IND and first in human programs worldwide, with deep expertise in regulatory strategy, toxicology, program design, and translational execution. His career spans senior executive leadership roles, CRO operations, and hands on scientific oversight across multiple therapeutic modalities.
He is recognized for disciplined development planning, risk mitigation, and capital efficient advancement of complex programs toward clinical milestones.